BMY240802C46000
- 3.40
- 0.000.00%
Bristol-Myers Squibb Newsroom
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $62
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
Barclays Cuts Bristol Myers to Underweight, Cites Recent Run up
Wolfe Adjusts Price Target on Bristol-Myers Squibb to $57 From $55, Maintains Outperform Rating
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Morgan Stanley Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Price Target Maintained With a $41.00/Share by Barclays
Bristol-Myers Squibb Analyst Ratings
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Uncertainties
Barclays Downgrades Bristol-Myers Squibb(BMY.US) to Sell Rating, Maintains Target Price $41
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Announces Target Price $62
Cantor Fitzgerald Raises Price Target on Bristol-Myers Squibb to $50 From $45
Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline
Deutsche Numis Initiates Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $45
Bristol-Myers Squibb Analyst Ratings
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained
Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects
Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns